Omeros (NASDAQ:OMER) VP Peter Cancelmo Sells 25,000 Shares of Stock

Omeros Corporation (NASDAQ:OMER) VP Peter Cancelmo sold 25,000 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $18.54, for a total value of $463,500.00. Following the sale, the vice president directly owned 200 shares in the company, valued at $3,708. This represents a 99.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Omeros Price Performance

Omeros stock opened at $18.75 on Wednesday. The firm has a market cap of $1.36 billion, a PE ratio of 14.65 and a beta of 2.60. The stock’s fifty day moving average price is $12.98 and its two-hundred day moving average price is $12.14. Omeros Corporation has a one year low of $3.94 and a one year high of $19.65.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.29. The company had revenue of $28.53 million for the quarter, compared to analyst estimates of $12.69 million. Sell-side analysts expect that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on OMER shares. HC Wainwright reissued a “buy” rating on shares of Omeros in a report on Monday, July 27th. Zacks Research downgraded shares of Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Weiss Ratings upgraded shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Finally, Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.00.

Institutional Trading of Omeros

Several large investors have recently bought and sold shares of the business. HighTower Advisors LLC raised its stake in Omeros by 4.3% during the second quarter. HighTower Advisors LLC now owns 115,368 shares of the biopharmaceutical company’s stock worth $1,097,000 after acquiring an additional 4,738 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Omeros in the second quarter worth about $146,000. California State Teachers Retirement System boosted its stake in shares of Omeros by 19,094.9% in the 2nd quarter. California State Teachers Retirement System now owns 720,192 shares of the biopharmaceutical company’s stock valued at $75,730,000 after purchasing an additional 716,440 shares in the last quarter. Compass Financial Management LLC bought a new stake in shares of Omeros during the 2nd quarter valued at approximately $312,000. Finally, Ancora Advisors LLC grew its holdings in shares of Omeros by 46.7% during the 2nd quarter. Ancora Advisors LLC now owns 168,750 shares of the biopharmaceutical company’s stock valued at $1,605,000 after purchasing an additional 53,750 shares during the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.